ライフサイエンスコーパス: cholecalciferol

1 150,000 IU (0.15 mU) or 300,000 IU (0.3 mU) cholecalciferol.

2 n subjects received placebo, and 25 received cholecalciferol.

3 rease in vitamin D receptor expression after cholecalciferol.

4 itamin D (calcidiol) to a large oral dose of cholecalciferol.

5 mented with a single oral dose of 100,000 IU cholecalciferol.

6 all women received supplemental calcium and cholecalciferol.

7 t containing 500 mg of calcium and 250 IU of cholecalciferol.

8 tients were randomized to receive placebo or cholecalciferol (100,000 IU load plus 4,000 IU/d) for 28

9 Cholecalciferol (100,000 IU) is a safe, effective, and s

10 y BMC of infants born to mothers assigned to cholecalciferol 1000 IU/day did not significantly differ

11 Supplementation of women with cholecalciferol 1000 IU/day during pregnancy did not lea

12 n randomly permuted blocks of ten, to either cholecalciferol 1000 IU/day or matched placebo, taken or

13 ned 569 pregnant women to placebo and 565 to cholecalciferol 1000 IU/day.

14 during winter and randomly assigned to oral cholecalciferol (1000 IU/day) versus placebo for 1 month

15 fter stratification by sex to receive either cholecalciferol (1200 IU/d) or a placebo for 16 wk.

16 ive, in addition to teriparatide and 1000 IU cholecalciferol, 1800 mg calcium/d as either tricalcium

17 randomized to receive either placebo or oral cholecalciferol, 2000 IU/d, with dose escalation to elev

18 e either two directly observed oral doses of cholecalciferol (300,000 IU) or matching placebo at base

19 All patients were prescribed vitamin D(3) (cholecalciferol) 400 IU and calcium carbonate 1,000 mg d

20 In this study, we examined the effects of cholecalciferol, a primary keratinocyte metabolite and p

21 At follow-up, 90.5% of subjects treated with cholecalciferol achieved serum 25(OH)D concentrations >/

22 All patients received 800 IU of cholecalciferol and 1,000 mg of calcium carbonate.

23 term hemodialysis and assessed changes after cholecalciferol and paricalcitol therapies in both vitam

24 e of iodine, cis/trans isomerisation of both cholecalciferol and pre-vitamin D3 takes place to form t

25 change in biomarkers for placebo, 200,000 IU cholecalciferol, and 400,000 IU cholecalciferol groups,

26 nonsignificant for calcium supplementation, cholecalciferol, and among men.

27 Metabolites of vitamin D3 (D3) (cholecalciferol) are recognized as enzymatically formed

28 One gram of calcium per day and oral cholecalciferol at a dosage of 100,000 IU every 2 mo adm

29 ,4-trideuterobutyl)-23-yn e-26,27-hexafluoro-cholecalciferol (BXL0124), on mammary tumor growth and C

30 0 ng/mL) patients with SLE were treated with cholecalciferol by their physician.

31 an adults and how daily supplementation with cholecalciferol changes these concentrations.

32 single dose of either dose of intramuscular cholecalciferol corrected vitamin D deficiency in the ma

33 re injected with either 1alpha,25-dihydroxy- cholecalciferol, cyclosporine A, or interleukin-10.

34 =1000 IU (25 microg) [corrected] vitamin D (cholecalciferol)/d is needed to bring vitamin D concentr

35 0,000 IU cholecalciferol followed by 4000 IU cholecalciferol/d or a matching placebo for 16 wk.

36 Healthy men seem to use 3000-5000 IU cholecalciferol/d, apparently meeting > 80% of their win

37 d with placebo, but did show that 1000 IU of cholecalciferol daily is sufficient to ensure that most

38 Serum calcidiol rose promptly after cholecalciferol dosing from a mean (+/-SD) baseline of 2

39 iferol-induced PGE2 production by inhibiting cholecalciferol-enhanced COX-2 mRNA and protein expressi

40 tion is primarily COX-2 dependent, and (iii) cholecalciferol enhances both COX-2 mRNA and protein exp

41 uded chlorthalidone, amlodipine, carvedilol, cholecalciferol, erythropoietin, and a phosphate binder.

42 ceive either a bolus oral dose of 100,000 IU cholecalciferol followed by 4000 IU cholecalciferol/d or

43 30,000 (n = 215) or 60,000 (n = 215) IU oral cholecalciferol for </=12 mo.

44 In SLE patients treated with cholecalciferol for 12 weeks, the improvement in endothe

45 doses labeled at 0, 25, 125, and 250 micro g cholecalciferol for approximately 20 wk during the winte

46 re post-partum haemorrhage than those in the cholecalciferol group (96 [17%] of 569 mothers in the pl

47 placebo group and 367 (65%) neonates in the cholecalciferol group had a usable DXA scan and were ana

48 cebo group vs 65 [12%] of 565 mothers in the cholecalciferol group; p=0.01).

49 , 200,000 IU cholecalciferol, and 400,000 IU cholecalciferol groups, respectively, were as follows: 1

50 People who were randomly assigned 60,000 IU cholecalciferol had nonsignificant 28% lower risk of hav

51 2 diabetes, short-term supplementation with cholecalciferol improved beta cell function and had a ma

52 dependently, suggesting a potential role for cholecalciferol in regulating the differentiation of hum

53 concentrations, there is very little native cholecalciferol in the body, and 25(OH)D constitutes the

54 Furthermore, cholecalciferol increased total cellular transglutaminas

55 Cholecalciferol induced PGE2 production, whereas 1alpha,

56 in kinase C inhibitor, significantly reduced cholecalciferol-induced PGE2 production by inhibiting ch

57 uce PGE2 biosynthesis in keratinocytes, (ii) cholecalciferol-induced PGE2 production is primarily COX

58 e quantitative relation between steady state cholecalciferol input and the resulting serum 25-hydroxy

59 ly 0.70 nmol/L for each additional 1 micro g cholecalciferol input.

60 The cholecalciferol inputs required to achieve or maintain a

61 nic HF due to LVSD and vitamin D deficiency (cholecalciferol <50 nmol/l [<20 ng/ml]).

62 Placebo (n = 10) versus 200,000 IU cholecalciferol (n = 10) versus 400,000 IU cholecalcifer

63 U cholecalciferol (n = 10) versus 400,000 IU cholecalciferol (n = 10), within 24 hours of new-onset s

64 /d, apparently meeting > 80% of their winter cholecalciferol need with cutaneously synthesized accumu

65 secondary aim was to determine the effect of cholecalciferol on blood pressure and serum fibroblast g

66 either placebo or a high dose of vitamin D3 (cholecalciferol) one hour after experimental sunburn ind

67 or uncontrolled-trials with vitamin D terms: cholecalciferol or hydroxycholecalciferols or calcifedio

68 Cholecalciferol or vitamin D3 is known to isomerise unde

69 rs the cutaneous production of vitamin D(3) (cholecalciferol) or the intestinal absorption of vitamin

70 eers, supplementation of vitamin D3 (4000 IU cholecalciferol per day) increased the number of circula

71 500 mg of calcium plus 700 IU of vitamin D3 (cholecalciferol) per day or placebo.

72 After 1 y, this oral cholecalciferol regimen was safe and sufficient to maint

73 ily requirement during winter that is met by cholecalciferol reserves in body tissue stores.

74 [1, 25(OH)2-16,23E-diene-26-trifluoro-19-nor-cholecalciferol (Ro 25-9716)] had an ED50 of 4 x 10(-11)

75 nd the analogue 1,25-dihydroxy-16-ene-23-yne-cholecalciferol (Ro23-7553) have significant in vitro an

76 mount of vitamin D (511 IU/d from diet and a cholecalciferol supplement) for 10 wk.

77 31.6 were randomly assigned to receive daily cholecalciferol supplementation at 1 of 2 doses (2000 or

78 We aimed to determine whether high-dose cholecalciferol supplementation for 1 y in early CKD is

79 Cholecalciferol supplementation increased total and meas

80 trolled trial, we investigated the effect of cholecalciferol supplementation on vascular function in

81 High-dose cholecalciferol supplementation rapidly and safely impro

82 Cholecalciferol supplementation resulted in increased se

83 Cholecalciferol supplementation significantly increased

84 nd efficacy of high-dose 25 (OH) vitamin D3 (cholecalciferol) supplementation in patients with chroni

85 Cholecalciferol therapy increased serum 25(OH)D levels f

86 Cholecalciferol therapy reduced circulating levels of in

87 -IU dose of vitamin D(3) had a rise in serum cholecalciferol to a mean of 521 nmol/L at 1 d and then

88 human trophoblasts were incubated with (13)C-cholecalciferol to examine the intracellular generation

89 obin concentrations, which were lower in the cholecalciferol-treated group (P < 0.04).

90 In cholecalciferol-treated patients, change in 25-hydroxyvi

91 accharide model, 1,500 IU of intraperitoneal cholecalciferol treatment 6 hours postinjury reduced alv

92 Short-term, high-dose oral cholecalciferol treatment of vitamin D deficiency in hem

93 Furthermore, serum PTH improved after cholecalciferol treatment, particularly in patients who

94 protein expression increased in response to cholecalciferol treatment.

95 1 expression did not increase in response to cholecalciferol treatment.

96 4A1 gene transcript abundance in response to cholecalciferol treatment.The numerous associations of m

97 ssion levels did not increase in response to cholecalciferol treatment; however, unlike COX-1 and cPL

98 Vitamin D (cholecalciferol, up to 500 IU/d) was provided if baselin

99 CKD (stages 2-3) were supplemented with oral cholecalciferol (vitamin D group; 50,000 IU/wk for 12 wk

100 ertain the efficacy of weekly very-high-dose cholecalciferol (vitamin D(3)) in correcting vitamin D i

101 at late summer and after 6-mo consumption of cholecalciferol (vitamin D(3))-fortified bread and milk.

102 All participants were prescribed daily cholecalciferol (vitamin D) and calcium.

103 ntrations of ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) (vitamin D) and 25-hydroxiv

104 pants were randomly assigned to receive oral cholecalciferol (vitamin D3) supplements of 400 IU/d (n=

105 Cholecalciferol was administered daily in controlled ora

106 hether oral supplementation of vitamin D(3) (cholecalciferol) will reduce the incidence and severity